Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 8/20 | 0.44 |
| ▸ | ARG2 | P78540 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | ODC1 | P11926 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3109344 | 1.00 | ARG1 (0.44) | ARG1ARG2MEN1KMT2AALDH1A1 | |
| SCHEMBL3146213 | 0.82 | ARG2 (0.45) | ARG1ARG2MEN1KMT2AALDH1A1 | |
| SCHEMBL31328787 | 0.82 | ARG1 (0.32) | ARG1ARG2MEN1KMT2AALDH1A1 | |
| SCHEMBL3146220 | 0.82 | ARG2 (0.45) | ARG1ARG2MEN1KMT2AALDH1A1 | |
| SCHEMBL1923397 | 0.81 | — | — | |
| SCHEMBL10512288 | 0.80 | ALDH1A1 (0.40) | ARG1ARG2MEN1KMT2AALDH1A1 | |
| SCHEMBL27476213 | 0.78 | MEN1 (0.54) | ARG1ARG2MEN1KMT2AALDH1A1 | |
| SCHEMBL10598985 | 0.75 | CYP1A2 (0.61) | ARG1ARG2MEN1KMT2AALDH1A1 | |
| SCHEMBL13953200 | 0.75 | MEN1 (0.41) | ARG1ARG2MEN1KMT2AALDH1A1 | |
| SCHEMBL6924741 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2239335-B1 | PROCESS FOR PRODUCTION OF SERINE DERIVATIVE, AND PROTEIN FOR USE IN THE PROCESS | AJINOMOTO KK (JP) | 2013-02-27 | — | — | EP | disclosed |
| US-8372607-B2 | Method for producing serine derivative and protein used for the same | AJINOMOTO CO., INC. (JP) | 2013-02-12 | — | — | US | disclosed |
| US-20100317068-A1 | METHOD FOR PRODUCING SERINE DERIVATIVE AND PROTEIN USED FOR THE SAME | AJINOMOTO CO., INC. (JP) | 2010-12-16 | — | — | US | disclosed |
| EP-2239335-A1 | PROCESS FOR PRODUCTION OF SERINE DERIVATIVE, AND PROTEIN FOR USE IN THE PROCESS | Ajinomoto Co., Inc. (JP) | 2010-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317068-A1 | METHOD FOR PRODUCING SERINE DERIVATIVE AND PROTEIN USED FOR THE SAME | SPR, AMD1, DAO | ARG1 3039/4885ARG2 3627/4885MEN1 3040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.